Product information	»
Mode of action	»
Preclinical results	»
Clinical oncological effects	»
Frequently asked questions	»
References	»

Indications

Avemar is a medical nutriment for complementing cancer treatment during and after surgery, radiotherapy, chemotherapy and immune therapy. The continuous use of Avemar is recommended during the full course of clinical treatment and after its completion for as long as recommended by the treating physician. After surgery, the administration of Avemar can begin when the patient has been able to take food orally and without complications for at least 4 days.

»	Review 1 The product and its registration status
»	Review 2 The Approved Avemar label

»	Product name
»	Composition
«	Indications
»	Mode of action
»	Preclinical anti-cancer effects
»	Clinical efficacy
»	Safety profile
»	Known interactions with other drugs
»	Warning
»	Preparation, dosage and administration

Home